Core Viewpoint - Vanda Pharmaceuticals Inc. has received FDA approval for BYSANTI™ (milsaperidone), marking a significant advancement in the treatment of bipolar I disorder and schizophrenia, which could enhance the company's position in the psychiatric innovation sector [1] Company Summary - Vanda Pharmaceuticals Inc. shares experienced a sharp increase in pre-market trading following the announcement of FDA approval for BYSANTI™ [1]

Core Insights - Vanda Pharmaceuticals has received FDA approval for BYSANTI™ (milsaperidone), a new treatment for Bipolar I Disorder and Schizophrenia, marking a significant advancement in psychiatric care [1][2] Company Overview - Vanda Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies to meet high unmet medical needs [2][3] - The approval of BYSANTI™ is the second new drug approval for Vanda within two months, following the approval of NEREUS™ in December 2025 [1] Product Details - BYSANTI™ is an atypical antipsychotic indicated for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for schizophrenia in adults [1][2] - The drug is a new chemical entity that shows bioequivalence to iloperidone, leveraging extensive clinical data and real-world experience [1] - BYSANTI™ is expected to be commercially available in Q3 of 2026, with patent protection extending until 2044 [1] Clinical Significance - Bipolar I disorder affects approximately 10 million Americans, while schizophrenia impacts about 2.8 million adults in the U.S., highlighting the need for effective treatments [1] - BYSANTI™ is currently being tested as a once-daily adjunctive treatment for treatment-resistant major depressive disorder [1] Safety and Efficacy - The safety profile of BYSANTI™ aligns closely with that of iloperidone, with a unique receptor binding profile that may allow for further investigation in related conditions [1] - Common adverse reactions include tachycardia, dizziness, and weight gain, with specific warnings for elderly patients and those with pre-existing conditions [2]